A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The NeAT Glio trial will evaluate whether the addition of ipilimumab prior to the current
standard treatment of surgery and chemoradiotherapy will improve survival in patients with
newly diagnosed glioblastoma.